CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 330 enrolled
Drug / intervention
No Interventionother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05882279
NCT05882279N/ACompleted
CompareCT.gov

Evaluation of the Effectiveness of Risk Minimization Measures: A Survey Among Pharmacists to Assess the Impact of the RMP Material for Patients on Promoting the Proper Use of NINLARO in Japan

Takeda·observational·Posted May 31, 2023·Updated Jun 14, 2024

In Brief

An observational study evaluating No Intervention for Multiple Myeloma. Completed, enrolled 330 participants across 1 site.

Detailed Summary

This is a survey among pharmacists who have instructed NINLARO therapy in ixazomib, lenalidomide and dexamethasone (IRD) dosing to patients with relapsed/refractory multiple myeloma (rrMM). The main aims of the study are: * To assess the frequency of pharmacists who have provided patients with the contents of the RMP material for patients. * To assess the frequency of pharmacists who have obtained the RMP material for patients. * To evaluate the depth of understanding of proper usage of NINLARO among pharmacists.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesJapan
Collaborators--

Timeline

N/ACompletedFinished
202420252026
First PostedMay 31, 2023
Enrollment StartJun 1, 2023
Primary CompletionJun 9, 2023
TodayJul 2, 2026
Enrollment to primary: 8 daysPosted 3.1 years ago

Interventions

No Interventionother

This is a non-interventional study.